REXN · Rexahn Pharmaceuticals, Inc

-

Please sign in to comment on REXN

1 Comment

Admin

4 years, 1 month ago

Rexahn Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 33.9% below its 200 day moving average.

From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.4.

Rexahn Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 28.4% to $-1M since the same quarter in the previous year.

Finally, its free cash flow grew by 52.9% to $-1M since the same quarter in the previous year.

Based on the above factors, Rexahn Pharmaceuticals, Inc gets an overall score of 3/5.

Exchange	NASDAQ
CurrencyCode	USD
Sector	Healthcare
Industry	Biotechnology
ISIN	US7616403090

Beta	0.97
Market Cap	2M
PE Ratio	None
Target Price	3
Dividend Yield	0.0%

ABOUT

Rexahn Pharmaceuticals, Inc

As of November 5, 2020, Rexahn Pharmaceuticals, Inc. was acquired by Ocuphire Pharma, Inc., in a reverse merger transaction. Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's product pipeline include RX-3117, which is in Phase IIa clinical trials for the treatment of patients with relapsed or refractory metastatic pancreatic cancer, as well as bladder, colon, lung and cervical cancer. It is also developing RX-0301, which is in preclinical development stage for the treatment of hepatocellular carcinoma. Rexahn Pharmaceuticals, Inc. has collaboration agreements with Zhejiang Haichang Biotechnology Co., Ltd.; and BioSense Global LLC. The company is headquartered in Rockville, Maryland.

REXN · Rexahn Pharmaceuticals, Inc

-

Rexahn Pharmaceuticals, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Rexahn Pharmaceuticals, Inc using a moving average strategy